StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) stock

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.23−0.25 (-3.86%)

Close on Nov 17, 2026Market cap $668.01MP/E –Yield –

Solid Biosciences total assets

Total assets on the balance sheet at the end of each period.

Solid Biosciences's total assets was $420.58M at Jun 30, 2026. For fiscal 2025 it was $232.54M, up 23.3% from the year before. The highest annual figure on record is $260.25M in fiscal 2022.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$232.54M+23.3%
FY2024Dec 31, 2024$188.66M+14.4%
FY2023Dec 31, 2023$164.94M-36.6%
FY2022Dec 31, 2022$260.25M+12.0%
FY2021Dec 31, 2021$232.38M+35.8%
FY2020Dec 31, 2020$171.17M+65.4%
FY2019Dec 31, 2019$103.47M-25.9%
FY2018Dec 31, 2018$139.60M+83.2%
FY2017Dec 31, 2017$76.19M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$420.58M+36.4%
Q1 FY2026Mar 31, 2026$422.89M+23.0%
Q4 FY2025Dec 31, 2025$232.54M+23.3%
Q3 FY2025Sep 30, 2025$273.91M+29.3%
Q2 FY2025Jun 30, 2025$308.29M+33.5%
Q1 FY2025Mar 31, 2025$343.90M+38.3%
Q4 FY2024Dec 31, 2024$188.66M+14.4%
Q3 FY2024Sep 30, 2024$211.83M+14.7%
Q2 FY2024Jun 30, 2024$230.98M+12.8%
Q1 FY2024Mar 31, 2024$248.69M+8.3%
Q4 FY2023Dec 31, 2023$164.94M-36.6%
Q3 FY2023Sep 30, 2023$184.73M+0.1%
Q2 FY2023Jun 30, 2023$204.72M-1.8%
Q1 FY2023Mar 31, 2023$229.59M+10.6%
Q4 FY2022Dec 31, 2022$260.25M+12.0%
Q3 FY2022Sep 30, 2022$184.47M-25.9%
Q2 FY2022Jun 30, 2022$208.50M-21.6%
Q1 FY2022Mar 31, 2022$207.56M-27.2%
Q4 FY2021Dec 31, 2021$232.38M+35.8%
Q3 FY2021Sep 30, 2021$248.99M+514.5%
Q2 FY2021Jun 30, 2021$265.86M+358.7%
Q1 FY2021Mar 31, 2021$285.28M+285.7%
Q4 FY2020Dec 31, 2020$171.17M+65.4%
Q3 FY2020Sep 30, 2020$40.52M-69.1%
Q2 FY2020Jun 30, 2020$57.96M-39.8%
Q1 FY2020Mar 31, 2020$73.96M-38.5%
Q4 FY2019Dec 31, 2019$103.47M-25.9%
Q3 FY2019Sep 30, 2019$130.93M-16.5%
Q2 FY2019Jun 30, 2019$96.30M-43.8%
Q1 FY2019Mar 31, 2019$120.23M-36.5%
Q4 FY2018Dec 31, 2018$139.60M+83.2%
Q3 FY2018Sep 30, 2018$156.81M–
Q2 FY2018Jun 30, 2018$171.47M–
Q1 FY2018Mar 31, 2018$189.24M–
Q4 FY2017Dec 31, 2017$76.19M–

More Solid Biosciences figures

See a number that looks wrong?